UPDATE: Goldman Sachs Upgrades Amgen to CL-Buy on Favorable Catalysts, Upside Potential

In a report published Wednesday, Goldman Sachs analyst Terence Flynn upgraded the rating on Amgen (NASDAQ: AMGN ) from Neutral to Conviction List Buy, and raised the price target from $100.00 to $130.00. In the report, Flynn noted, “We switch to AMGN from BIIB, as we see a more favorable